Widespread incidences of various diseases such as cancer, diabetes, cardiovascular and neurological disorders, among others coupled with the growing technological advancements are expected to bolster the growth of the Europe biomarker technologies market
Speak directly to the analyst to clarify any post sales queries you may have.
10% Free customizationThis report comes with 10% free customization, enabling you to add data that meets your specific business needs.
Europe biomarker technologies market is segmented into test type, technology, product, indication, end user, application, and country. Based on indication, the market can be segmented into oncology, infectious diseases, autoimmune disorders, cardiovascular disorders and others. Among them, the cardiovascular disorders segment is expected to undergo fastest CAGR during the forecast period owing to rise in number of people suffering from cardiovascular diseases.
Based on application, Europe biomarker technologies market is segmented into clinical diagnostics, research and drug discovery & development. Among these, the drug discovery segment is expected to witness significant growth through 2028 as biomarker technologies are helpful in drug discovery particularly for cancer and cardiovascular diseases.
Major players operating in the Europe biomarker technologies market are F. Hoffmann-La Roche AG, Merck KGAA, Beckman Coulter, Inc., Qiagen N.V., Biomérieux SA, Bio-Rad Laboratories N.V., Siemens AG, Abbott Molecular Inc., Danaher Corporation, and Epigenomics AG. The companies are undergoing growth strategies such as mergers & acquisitions and product innovation.
Objective of the Study:
To analyze and estimate the market size of Europe biomarker technologies market from 2018 to 2021.To estimate and forecast the market size of Europe biomarker technologies market from 2022 to 2028 and growth rate until 2028.
To classify and forecast Europe biomarker technologies market based on test type, technology, product, indication, end user, application, company, and country.
To identify dominant country or segment in the Europe biomarker technologies market.
To identify drivers and challenges for Europe biomarker technologies market.
To examine competitive developments such as expansions, mergers & acquisitions, etc., in Europe biomarker technologies market.
To identify and analyze the profile of leading players operating in Europe biomarker technologies market.
To identify key sustainable strategies adopted by market players in Europe biomarker technologies market.
The publisher performed both primary as well as exhaustive secondary research for this study. Initially, The research team sourced a list of biomarker technologies companies across Europe. Subsequently, The research team conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, the publisher could include the companies who could not be identified due to the limitations of secondary research. The research team analyzed the presence of all major players across Europe.
The publisher calculated the market size of Europe biomarker technologies market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. The research team sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these services and end users for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied.
Key Target Audience:
- Biomarker technology companies, vendors, end users and other stakeholders
- Government bodies such as regulating authorities and policy makers
- Organizations, forums, and alliances related to biomarker technologies
Market research and consulting firms
The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as biomarker technology companies, vendors, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.Report Scope:
In this report, Europe biomarker technologies market has been segmented into following categories, in addition to the industry trends which have also been detailed below:Europe Biomarker Technologies Market, By Test Type:
- Solid Biopsy
- Liquid Biopsy
Europe Biomarker Technologies Market, By Technology:
- Immunoassay
- DDPCR
- Next Generation Sequencing (NGS)
- Mass Spectrometry
- DHPLC
- Others
Europe Biomarker Technologies Market, By Product:
- Consumables
- Instruments
- Services
- Software/Informatics
Europe Biomarker Technologies Market, By Indication:
- Oncology
- Infectious Diseases
- Autoimmune Disorders
- Cardiovascular Disorders
- Others
Europe Biomarker Technologies Market, By End User:
- Pharmaceutical Companies
- Hospitals
- CROs
- Diagnostic Labs
- Research Institutes
Europe Biomarker Technologies Market, By Application:
- Clinical Diagnostics
- Research
- Drug Discovery & Development
Europe Biomarker Technologies Market, By Country:
- Italy
- France
- United Kingdom
- Germany
- Spain
- Belgium
- Netherlands
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Europe biomarker technologies market.Available Customizations:
With the given market data, the publisher offers customizations according to a company’s specific needs. The following customization options are available for the report:Company Information
Detailed analysis and profiling of additional market players (up to five).Profit Margin Analysis
Profit margin analysis in case of direct and indirect sales channel.This product will be delivered within 1-3 business days.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- F. Hoffmann-La Roche AG
- Merck KGAA
- Beckman Coulter, Inc.
- Qiagen N.V.
- Biomérieux SA
- Bio-Rad Laboratories N.V.
- Siemens AG
- Abbott Molecular Inc.
- Danaher Corporation
- Epigenomics AG